Navigation Links
Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine
Date:10/26/2009

BRAINTREE, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that Dr. Mark Popovsky, Vice President and Chief Medical Officer, has been awarded the Emily Cooley Memorial Award and Lectureship by AABB. The Memorial Award was founded as a lectureship in 1963 and is given annually to a person who has demonstrated teaching ability and made a major contribution to the fields of immunohematology, transfusion medicine, and cellular therapies.

"The Emily Cooley Memorial Award and Lectureship is an excellent recognition of Dr. Popovsky's dedication to and impact on the transfusion industry. We are honored to have Dr. Popovsky as part of our team and congratulate him on this award," said Brian Concannon, President and CEO of Haemonetics.

Dr. Popovsky joined Haemonetics in 2000 as Corporate Medical Director and President of the Cell Processing Division. In addition to his work at Haemonetics, he is currently an Associate Clinical Professor of Pathology at Harvard Medical School and Beth Israel Deaconess Medical Center. Dr. Popovsky currently serves on the editorial board of 5 journals. He has authored, or co-authored, over 375 publications in transfusion medicine and pathology. He is editor and co-editor of two reference books in transfusion medicine. In 2004, he served in Nigeria as a member of the U.S. President's Emergency Plan for AIDS Relief delegation to that country.

Prior to Haemonetics, Dr. Popovsky was with the American Red Cross, New England Region, where he held the positions of Medical Director and then Chief Executive Officer. He also served as Director of the Transfusion and Intravenous Services at the Mayo Clinic. Dr. Popovsky is an honors graduate of the University of Vermont, College of Medicine.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

    Contact:
    Julie Fallon
    Tel. (781) 356-9517
    Alt. Tel. (617) 320-2401

SOURCE Haemonetics Corporation


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmalink AB Receives Patent for Nefecon(R) Principle
2. Solos Endoscopy, Inc. Receives Additional Purchase Orders from National Cancer Institute and National Institute of Health for its MammoView(TM) Product Line
3. Ikaria Receives Award for Excellence by New Jersey Business & Industry Association
4. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
5. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
6. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
7. Solos Endoscopy, Inc. Receives Multiple Purchase Orders for its MammoView(TM) Product Line
8. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
9. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
10. AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure
11. Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... management skills and infrastructure. Most providers, however, are unsure how to move forward, ... Ascend to define a path forward tailored to an organization’s specific needs. ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 on ... head and neck cancer in individuals with unhealthy oral hygiene habits. The article goes ... whether they had gum disease, brushed their teeth on a daily basis, wore dentures ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... today announced SentinelSecure™, its containerized mobile security software, is featured in the current ... online community that identifies leading companies with innovative technology solutions and features them ...
Breaking Medicine News(10 mins):